利那洛肽临床使用专家会议纪要  

Summary Report of Expert Seminar on Clinical Use of Linaclotide

作　　者：白涛[1] 侯晓华[1] BAI Tao;HOU Xiaohua(Department of Gastroenterology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022)

机构地区：[1]华中科技大学同济医学院附属协和医院消化内科,430022

出　　处：《胃肠病学》2021年第8期486-488,共3页Chinese Journal of Gastroenterology

摘　　要：利那洛肽是我国首个获批用于治疗便秘型肠易激综合征的促分泌剂。2021年6月26日国内部分消化病学领域专家对利那洛肽在我国的临床使用情况进行了专题讨论。与会专家认为,应基于便秘和腹部症状的改善情况综合评价利那洛肽的临床疗效,需重视患者满意度,同时可根据患者的治疗应答、生活习惯、症状严重程度、药物敏感度等因素,优化利那洛肽的服用时间、剂量和疗程。此外,应加强与患者的沟通,帮助其建立合理的疗效预期,并根据其反馈及时优化治疗方案。Linaclotide is the first secretagogue approved for the treatment of irritable bowel syndrome with constipation in China.A group of experts in digestive diseases was convened to discuss the clinical use of linaclotide in China on June 26,2021.Experts concluded at the seminar that the clinical efficacy of linaclotide should be comprehensively evaluated based on the improvement of constipation and abdominal symptoms;the clinicians should emphasize the importance to patient satisfaction;and the administration time,dose and duration of linaclotide treatment can be optimized according to the treatment response,lifestyle,severity of symptoms and drug sensitivity.In addition,the experts believed that communication with patients should be strengthened to help them to establish reasonable expectations to the efficacy and optimize the treatment regimen timely according to their feedback.

关 键 词：利那洛肽 肠易激综合征 便秘 腹痛 鸟苷酸环化酶C 

分 类 号：R47[医药卫生—护理学]